Brokerages Set Zoetis Inc. (NYSE:ZTS) PT at $109.62

by · The Markets Daily

Zoetis Inc. (NYSE:ZTS – Get Free Report) has earned a consensus rating of “Hold” from the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $109.6154.

ZTS has been the topic of several analyst reports. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. UBS Group dropped their price objective on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. BNP Paribas Exane cut their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Barclays reduced their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st.

Get Our Latest Analysis on ZTS

Zoetis Trading Down 2.9%

NYSE:ZTS opened at $73.64 on Wednesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis has a one year low of $71.45 and a one year high of $160.48. The company has a market cap of $30.43 billion, a PE ratio of 12.13, a PEG ratio of 1.31 and a beta of 0.74. The firm has a 50-day moving average of $76.30 and a 200-day moving average of $99.01.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts expect that Zoetis will post 6.19 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s payout ratio is 34.93%.

Institutional Investors Weigh In On Zoetis

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZTS. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its position in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the period. Finally, Glenview Trust co lifted its holdings in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after acquiring an additional 506 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

(Get Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Further Reading